RxDoctor Payments Data

Archis Desai, MD

Internal Medicine · Redlands, CANPI 1396141230

Payments from drug & device makers

$4,796in general payments, 2019–2025

Across 236 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$1K
  • Johnson & Johnson$972
  • AbbVie$509
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$451
  • Sunovion Pharmaceuticals Inc.$411
  • Otsuka America Pharmaceutical, Inc.$339
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$4,796100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,796 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$774,987
Medicare patients
151
Services billed
6,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium101$65,007
EliquisApixaban33$21,676
XareltoRivaroxaban33$20,558
Combivent RespimatIpratropium/Albuterol Sulfate29$18,467
JanuviaSitagliptin Phosphate21$11,632
JardianceEmpagliflozin19$10,700
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$7,927
JanumetSitagliptin Phos/Metformin Hcl19$7,520
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,965
Albuterol Sulfate HfaAlbuterol Sulfate148$5,778
Serevent DiskusSalmeterol Xinafoate12$4,867
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen404$4,786
Dexlansoprazole DrDexlansoprazole14$3,199
Janumet XrSitagliptin Phos/Metformin Hcl11$2,913
Lubiprostone11$2,816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr$14$22,06451 claims
Johnson & JohnsonXarelto$972$20,55833 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Redlands

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →